Anti B cell therapy (rituximab) in the treatment of autoimmune diseases

Current Opinion in Pharmacology

Volumn 4, Issue 4, 2004, Pages 398-402

  Kazkaz, Hanadi ^a   Isenberg, David ^a  

^a MIDDLESEX HOSPITAL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA2A INTERFERON; B LYMPHOCYTE ANTIGEN; CD20 ANTIGEN; CHIMERIC ANTIBODY; COLD AGGLUTININ; CYCLOPHOSPHAMIDE; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOLOGICAL ADJUVANT; INTERLEUKIN 2; METHOTREXATE; MONOCLONAL ANTIBODY; PREDNISOLONE; RITUXAM; RITUXIMAB; STEROID;

ANTIBODY DEPENDENT CELLULAR CYTOTOXICITY; ARTICLE; AUTOIMMUNE DISEASE; B LYMPHOCYTE ACTIVATION; CLINICAL TRIAL; COMPLEMENT ACTIVATION; CRYOGLOBULINEMIA; DRUG DOSE REGIMEN; DRUG EFFICACY; DRUG MECHANISM; DRUG MEGADOSE; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; HUMAN; IDIOPATHIC THROMBOCYTOPENIC PURPURA; NEUROPATHY; NONHODGKIN LYMPHOMA; PATHOGENESIS; PRIORITY JOURNAL; RHEUMATOID ARTHRITIS; SIDE EFFECT; SYSTEMIC LUPUS ERYTHEMATOSUS;

EID: 3342930614     PISSN: 14714892     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.coph.2004.03.006     Document Type: Review

References (31)

1. Bubien J.K. Zhou L-J. Bell P.D. Frizzell R.A. Tedder T.F. Transfection of the CD20 cell surface molecule into ectopic cell types generates a Ca2+ conductance found constitutively in B-lymphocytes J Cell Biol 121 1993 1121-1132
2. Reff M.E. Carner K. Chambers K.S. Chinn P.C. Leonard J.E. Newman R.A. Hanna N. Anderson D.R. Depletion of B cells in vivo by a chimeric mouse human monoclonal antibody to CD20 Blood 83 1994 435-445
3. Maloney D.G. Smith B. Rose A. Rituximab:mechanism of action and resistance Semin Oncol 29Suppl 2 2002 2-9
4. McLaughlin P. Rituximab: perspective on single agent experience, and future direction in combination trials Crit Rev Oncol Hematol 40 2001 3-16
5. Cohen Y. Solal-Celigny P. Polliack A. Rituximab therapy for follicular lymphoma: a comprehensive review of its efficacy as primary treatment, treatment for relapsed disease, re-treatment and maintenance Haematologica 88 2003 811-823
6. McLaughlin P. Grillo-Lopez A.J. Link B.K. Levy R. Czuczman M.S. Williams M.E. Heyman M.R. Bence-Bruckler I. White C.A. Cabanillas F. et al. Rituximab chimeric anti-CD20 monoclonal antibody therapy for relapsed indolent lymphoma:half of patients respond to a four-dose treatment program J Clin Oncol 16 1998 2825-2833
7. Treon S.P. Anderson K.C. The use of Rituximab in the treatment of malignant and non malignant plasma cell disorders Semin Oncol 27 Suppl 12 2000 79-85
8. Marcelin A.G. Aaron J. Mateus G. Gyan E. Gorin I. Viard J.P. Calvez V. Dupin N. Rituximab therapy for HIV associated Castleman's disease Blood 102 2003 2786-2788
9. Edwards J.C.W. Cambridge G. Sustained improvement in rheumatoid arthritis following a protocol designed to deplete B lymphocytes Rheumatology 40 2001 205-211
10. Leandro M.J. Edwards J.C.W. Cambridge G. Clinical outcome in 22 patients with rheumatoid arthritis treated with B lymphocyte depletion Ann Rheum Dis 61 2002 883-888
11. De Vita S. Zaja F. Sacco S. De Candia A. Fanin R. Ferracccioli G. Efficacy of selective B cell blockade in the treatment of rheumatoid arthritis. Evidence for pathogenic role of B cells Arthritis Rheum 46 2002 2029-2033
12. Stahl HD, Szczepanski, Szechinski J, Filipowicz-Sosnowska A, Edwards JCW, Clase DR, Stevens RM, Shaw TM: Rituximab in rheumatoid arthritis: efficacy and safety from a randomised controlled trial. Ann Rheum Dis 2003, 62 (Suppl) :0P004.
13. Maini R. St Clair E.W. Breedveld F. Frust D. Kalden J. Weisman M. Smolen J. Emery P. Harriman G. Feldman M. Lipsky P. Infliximab(chimeric anti-tumour necrosis factor alpha monoclonal antibody)versus placebo in rheumatoid arthritis patients receiving concomitant methotrexate: a randomised phase III trial. ATTRACT study group Lancet 354 1999 1932-1939
14. Anolik J.H. Campbell D. Felgar R. Rosenblatt J. Young F. Looney R.J. B lymphocyte depletion in the treatment of systemic lupus (SLE): phase I/II trial of rituximab (Rituxan®) in SLE [abstract] Arthritis Rheum 46 2002-S289
15. Leandro M.J. Edwards J.C. Cambridge G. Ehrenstein M.R. Isenberg D.A. An open study of B lymphocyte depletion in systemic lupus erythermatosus Arthritis Rheum 46 2002 2673-2677
16. Looney R.J. Treating human autoimmune disease by depleting B cells Ann Rheum Dis 61 2002 863-866
17. Berentsen S. Tjonnfjord G.E. Brudevold R. Gjertsen B.T. Langhoim R. Lokkevik E. Sorbo J.H. Ulvestad E. Favourable resopnse to the therapy with the anti -CD20 monoclonal antibody rituximab in primary chronic cold agglutinin disease Br J Haematol 115 2001 79-83
18. Berensten S. Ulvestal E. Gjertsen B.T. Hjorth-Hanson H. Langholm R. Knutsen I.I. Ghanima W. Shammas F.V. Tjonnfjord G.E. Rituximab for primary chronic cold agglutinin disease: a prospective study of 37 courses of therapy in 27 patients Blood 103 2004 2925-2928
19. Aherns N. Kingreen D. Seltsam A. Salama A. Treatment of refractory autoimmune haemolytic anaemia aith snti-CD20(rituximab) Br J Haematol 114 2001 244-245
20. Saleh M.N. Guthril J. Moore M. Bunch P.W. Butler J. Kunkel L. Grillo-Lopez A.J. LoBuglio A.F. A pilot study of the anti-CD20 monoclonal antibody rituximab in patients with refractory immune thrombocytopenia Semin Oncol 27 Suppl 12 2000 99-103
21. Giagounidis A.A. Anhuf J. Schneider P. Germing U. Sohngen D. Quabeck K. Aul C. Treatment of relapsed idiopathic thrombocytopenic purpura with the anti-CD20 monoclonal antibody rituximab:a pilot study Eur J Haematol 69 2002 95-100
22. Stasi R. Pagano A. Stipa E. Amadori S. Rituximab chimeric anti-CD20 monoclonal antibody treatment for adults with chronic idiopathic thrombocytopenic purpura Blood 98 2001 952-957
23. Zecca M. De Stefano P. Nobili B. Locatelli F. Anti-CD20 monoclonal antibody for the treatment of severe, immune-mediated, pure red cell aplasia and hemolytic anemia Blood 97 2001 3995-3997
24. Auner H.W. Wolfer A. Beham-Schmid C. Strunk D. Linkesch W. Still H. Restoration of erythropoiesis by rituximab in an adult patient with primary acquired red cell aplasia refractory to conventional treatment Br J Haematol 116 2002 725-728
25. Levine T.D. Pestronk A. IgM antibody-related polyneuropathies: B cell depletion chemotherapy using rituximab Neurology 52 1999 1701-1704
26. Pestronak A. Florence J. Miller I. Choksi R. Al-Lozi M.T. Levine T.D. Treatment of IgM antibody associated polyneuropathies using rituximab J Neurol Neurosurg Physchiatry 74 2003 485-489
27. Zaja F. De Vita S. Mazzaro C. Sacco S. Damiani D. De Marchi G. Michelutti A. Baccarani M. Fanin R. Ferraccioli G. Efficacy and safety of rituximab in type II mixed cryoglobulinemia Blood 101 2003 3827-3834
28. Levine T.D. A pilot study of rituximab therapy for refractory dermatomyositis Arthritis Rheum 46 Suppl 9 2002 S1299
29. Dupay A. Viguier M. Bedane C. Cordoliani F. Blaise S. Aucouturier F. Bonnnetblanc J. Morel P. Dubertret L. Bachdez H. Treatment of refractory pemphigus vulgaris with rituximab (anti-CD20 monoclonal antibody) Arch Dermatol 140 2004 91-95
30. Specks U. Fervenza F.C. McDonald T.J. Hogan M.C.E. Response of Wegener's granulomatosis to anti-CD20 chimeric monoclonal antibody therapy Arthritis Rheum 44 2001 2836-2840
31. Zaja F. Russo D. Fuge G. Perella G. Baccarani M. Rituximab for myasthenia gravis developing after bone marrow transplant Neurology 55 2000 1062-1063